Sapu BioScience

Executive Summary

Sapu BioScience is a private, clinical-stage immuno-oncology company headquartered in San Diego, CA. Founded in 2019, the company focuses on developing first-in-class RNA therapeutics and small molecule drugs for cancer and infectious diseases. Its lead candidate, OT-101, is an anti-TGF-β RNA therapeutic that has demonstrated clinical activity in refractory cancers and against SARS-CoV-2. The TGF-β pathway is a promising target in immuno-oncology due to its role in immune evasion and tumor progression. Sapu's platform combines RNA-based modulation with small molecule approaches, positioning it uniquely in the competitive landscape. OT-101 is currently in clinical trials for multiple refractory solid tumors, with early data suggesting tolerability and signs of efficacy. The company is also exploring its potential in infectious diseases, though the COVID-19 opportunity has diminished. Key upcoming milestones include completion of Phase 2 expansion cohorts and potential regulatory interactions for pivotal trial design. As a private entity, Sapu's visibility is limited, but its differentiated approach and early clinical validation warrant attention. Risks include financing uncertainty and reliance on a single lead asset.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for OT-101 in refractory solid tumors70% success
• Q3 2026FDA Orphan Drug Designation for OT-101 in pancreatic cancer60% success
• 2026IND filing for next-generation RNA therapeutic candidate50% success